Johnson & Johnson Survey Highlights Heavy Burden of Bladder Cancer Treatments
WASHINGTON, May 14, 2026 Johnson & Johnson released findings from a groundbreaking global survey revealing the significant physical, emotional,...
NMIBC
Advertisement
UroGen Reports Strong Phase 3 UGN-103 Bladder Cancer Data
PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...
CG Oncology Reports Strong Phase 2 Results in High-Risk NMIBC
DALLAS, May 15, 2026 CG Oncology announced positive initial Phase 2 data from the CORE-008 Cohort CX trial, evaluating...
AstraZeneca VOLGA Trial Boosts Bladder Cancer Survival
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
Galmed Reports 500% Bioavailability Boost for Aramchol
RAMAT-GAN, Israel, May 14, 2026 Galmed Pharmaceuticals Ltd. announced positive results from its first-in-human pharmacokinetics study evaluating the oral...
Advertisements
Protara Reports Strong Phase 2 NMIBC Trial Results
NEW YORK, May 15, 2026 Protara Therapeutics, Inc. announced positive updated 12-month data from the fully enrolled BCG-Naïve cohort...
ImmunityBio to Present ANKTIVA Data at AUA 2026
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
Johnson & Johnson INLEXZO Gets J-Code for Cancer Access
RARITAN, N.J., USA — April 1, 2026 Johnson & Johnson announced that its innovative bladder cancer therapy INLEXZO™ (gemcitabine...
MVR-T3011 Posts 100% RFS in BCG-Naïve NMIBC
SUZHOU, China, February 26, 2026 ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
Advertisement
